Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience (NASDAQ:LEXX) has initiated dosing in its human study GLP-1-H25-5, comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. The study focuses on pharmacokinetics and safety assessment.
A previous 12-week rodent study showed that oral DehydraTECH-liraglutide achieved:
- 5.88% weight reduction
- 11.54% blood sugar reduction
Earlier GLP-1 PK studies in humans demonstrated that certain oral DehydraTECH formulations showed superior bloodstream delivery and reduced adverse events compared to existing oral semaglutide and injectable tirzepatide products. Currently, liraglutide is only available as an injectable under Saxenda® and Victoza® brands. Despite Teva's generic version launch in June 2024, Novo Nordisk generated $1.0 billion in Saxenda® revenue and $0.8 billion in Victoza® revenue during 2024.
Lexaria Bioscience (NASDAQ:LEXX) announced positive results from Human Study #3 comparing oral DehydraTECH-tirzepatide capsules to injectable Zepbound®. The study showed that oral capsules achieved comparable blood concentration levels to injections by the study's end.
Key findings from the 8-day study of 19 participants revealed that while injected Zepbound® typically peaked on Day 2 and declined, DehydraTECH-tirzepatide levels increased steadily daily. The oral version demonstrated:
- 47% fewer adverse events (20 vs 38)
- 54% reduction in gastrointestinal side effects
- Similar blood glucose reduction and insulin increase by Day 8
The company is now conducting a 12-week Phase 1b registrational study in Australia, starting at 20mg/day for 4 weeks and escalating to 40mg/day for the remaining 8 weeks. This extended study aims to evaluate steady-state blood levels and potentially demonstrate increased delivery and efficacy.
Lexaria Bioscience (NASDAQ:LEXX) has outlined its triple-pronged strategy in the GLP-1 drug sector, focusing on its DehydraTECH technology. The strategy includes: collaborating with pharmaceutical companies through material transfer agreements; developing patented DehydraTECH-CBD products for GLP-1 applications; and investigating an oral version of liraglutide.
The company's DehydraTECH technology addresses two major challenges in GLP-1 drugs: injection administration and gastrointestinal side effects. Clinical testing has shown DehydraTECH's delivery superiority to Rybelsus, the only existing oral GLP-1 drug. The technology has demonstrated reduced side effects in both tirzepatide and semaglutide.
This development comes as the FDA recently approved Ozempic (semaglutide) for chronic kidney disease treatment in type 2 diabetes patients. The GLP-1 sector is expected to generate over $100 billion in annual revenue, with some forecasts reaching $471 billion.
Lexaria Bioscience (NASDAQ:LEXX) has received lead clinical site human research ethics committee (HREC) approval for the 5th study arm of its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia. This follows the November 13, 2024 approval for the first 4 arms. The study includes five arms: DehydraTECH-CBD capsules, DehydraTECH-semaglutide capsules, DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules, Rybelsus® tablets, and DehydraTECH-tirzepatide capsules.
The study commenced with First Patient First Dose in December 2024. Additional HREC approval for other clinical sites is pending and expected soon. The study aims to evaluate the potential enhancement of GLP-1 drugs through Lexaria's DehydraTECH delivery technology, focusing on oral administration rather than injections.
Lexaria Bioscience (NASDAQ:LEXX) has announced its strategic pursuit of developing the world's first oral version of liraglutide using their DehydraTECH technology. The company has filed patent applications following successful animal studies that showed DehydraTECH-liraglutide outperformed Rybelsus control group by 11.53% in blood sugar control and 11.13% in body weight control by week 12.
The company has received ethics board approval to commence human pilot study GLP-1-H25-5, comparing oral DehydraTECH-processed Saxenda to conventional injected liraglutide. This initiative is part of Lexaria's broader strategy to enter the GLP-1 weight loss and diabetes control market, which has grown from $300 million in 2018 to approximately $30 billion in 2024.
Currently, liraglutide is only available in injectable form under Saxenda and Victoza brands by Novo Nordisk, generating $849 million in H1 2024 and $1.6 billion in recent annual revenue respectively.
Lexaria Bioscience (Nasdaq: LEXX) has been granted two new patents from the United States Patent and Trademark Office for its DehydraTECH enhanced processing technology in epilepsy treatment. These represent the company's 5th and 6th US patents in its patent family #24, 'Compositions and Methods for Treating Epilepsy,' bringing Lexaria's total granted patents to 48.
The patents, set to expire in 2043 unless extended, build upon previous research demonstrating that DehydraTECH-CBD could mitigate epileptic seizures in rodents and showed superior bloodstream absorption compared to Epidiolex, a commercial cannabinoid-based anti-seizure medication.
Lexaria Bioscience (Nasdaq:LEXX) has initiated a groundbreaking rodent biodistribution study to track DehydraTECH-processed semaglutide. The study aims to compare the biodistribution patterns of DehydraTECH-processed semaglutide against conventional Rybelsus®-like formulations.
The research utilizes fluorescently tagged semaglutide (FTS) in Sprague-Dawley rats, examining distribution patterns in key tissues including brain, pancreas, lung, kidney, liver, and heart. The study incorporates two test formulations: one mimicking Rybelsus® without DehydraTECH, and another using Lexaria's patented DehydraTECH process.
The study employs immunofluorescence methodology to detect GLP-1 receptor binding, providing detailed insights into tissue distribution and localization patterns. Results will be used to enhance communications with potential industry partners.
Lexaria Bioscience (NASDAQ:LEXX) has provided updates on its ongoing Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia. The company has completed its submission to the human research ethics committee (HREC) to add Study Arm 5, which will evaluate the performance of its DehydraTECH-tirzepatide formulation. This addition follows positive findings from their previous Human Pilot Study #3.
The company has received HREC approval for all 4 original arms across all participating clinical sites, following earlier approval for the lead clinical site. Clinical test article manufacturing has been completed. The company's previous Human Pilot Study #3 demonstrated comparable results in blood glucose reduction and insulin levels, along with significantly reduced adverse events when Eli Lilly's Zepbound® was processed with Lexaria's DehydraTECH™ technology.
Lexaria Bioscience (NASDAQ:LEXX) released its annual CEO letter highlighting significant achievements in 2024, particularly in GLP-1 drug delivery technology. The company raised $13.4M net through equity raises and warrant exercises, while its stock price increased 68% during the year.
Key developments included successful completion of multiple studies demonstrating positive results with DehydraTECH technology for GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. Notable outcomes included 18.8% higher semaglutide levels and 60% reduction in adverse events compared to Rybelsus®.
The company launched its first Phase 1b registrational study in Australia and received FDA clearance for a Phase 1b hypertension study. Lexaria secured 8 additional patents, expanding its portfolio to 46 patents worldwide, and entered into a Material Transfer Agreement with a pharmaceutical company for pre-clinical evaluation of DehydraTECH technology.
Lexaria Bioscience Corp. (LEXX) has received independent ethics board approval for its human pilot study GLP-1-H25-5, which will compare oral DehydraTECH-liraglutide to injectable Saxenda®. This follows successful animal studies where oral DehydraTECH-liraglutide showed a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline.
The study will involve 8-10 healthy volunteers to demonstrate safety and pharmacokinetic performance of orally dosed DehydraTECH-liraglutide. Positive results could lead to a Phase I registered trial. Liraglutide, currently sold only as injectable Saxenda® and Victoza®, generated US$849 million (Saxenda®) in H1 2024 and US$1.6 billion (Victoza®) in recent annual revenue.